XAll Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
XAll Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
In this brief report, the authors evaluate the effects of a possible association between different bupropion formulations and treatment-emergent insomnia in veterans with major depressive disorder prescribed bupropion based on provider discretion.
This study examined characteristics of pediatric psychiatric inpatients who experienced seclusion and restraint events and assessed if sleep time before and after the event was different from average sleep time during hospitalization.
Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
Insomnia and short sleep duration are linked to increased morbidity from cardiometabolic and neuropsychiatric disorders. This study investigated the prevalence and common clinical correlates of insomnia with subjective short sleep duration.
Individuals with narcolepsy may experience not only academic, social, and occupational consequences but also dangerous driving or other accidents, meaning that effective treatment is critical. Here, review the evidence on treatment strategies.
Aside from intramuscular injection, few rapidly acting pharmacotherapeutic treatments are available for acute agitation. This study examined the safety and tolerability of INP105, a drug-device combination product that allows nasal delivery of olanzapine.
For people living with Alzheimer's disease, sleep disturbances are often problematic for the patient and their family. In this CME webcast, watch short videos to gain insight from experts into the recognition and treatment of insomnia in these patients.
A fast-growing treatment for sleep is melatonin; however, research is scarce regarding the pharmacokinetics of different oral melatonin dosages. This study examined the pharmacokinetic and safety profile of a 7-hour continuous release and absorption melatonin.
A fast-growing treatment for sleep is melatonin; however, research is scarce regarding the pharmacokinetics of different oral melatonin dosages. This study examined the pharmacokinetic and safety profile of a 7-hour continuous release and absorption melatonin.
When sleep escapes you, it's hard to escape the pervasive feelings that accompany exhaustion. If improving sleep hygiene doesn' t work, can resetting one's qi help? This sham-controlled trial tests acupuncture for its short- and long-term effects.Â
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”